Amgen and UCB's romosozumab shows significant increase in BMD

US biotech firm Amgen (Nasdaq: AMGN) and partner UCB (Euronext Brussels: UCB) of Belgium have announced positive results from a Phase II trial evaluating romosozumab (AMG 785/CDP7851) in postmenopausal women with low bone mineral density (BMD).

Published in the New England Journal of Medicine (NEJM), the trial demonstrated that, compared with placebo, romosozumab treatment for 12 months significantly increased BMD at the lumbar spine, total hip and femoral neck, noted the companies, which early last year decided not to proceed with Phase III studies of the drug in fracture healing (The Pharma Letter February 13, 2013).

Beat Fosamax and Forteo